Clinical Trials Logo

Filter by:
NCT ID: NCT01175187 Enrolling by invitation - Clinical trials for Histological Placental Inflamation With or Without Fever

Intrapartum Fever and Histopathological Placental Findings

Start date: April 2009
Phase: Phase 4
Study type: Observational

Intrapartum fever associated with epidural anesthesia is caused by non infectious causes therefore without histological findings

NCT ID: NCT02070263 Enrolling by invitation - Food Allergy Clinical Trials

Mixed Tree Nut Food Challenges

Start date: April 2009
Phase:
Study type: Observational

The purpose of this prospective study is twofold: 1) to establish oral tolerance to selected tree nuts and to examine potential predictors of oral tolerance and 2) to determine the usefulness of mixed tree nut allergen food challenges in more efficiently defining tree nut allergy and oral tolerance.

NCT ID: NCT01082016 Enrolling by invitation - Sleep Deprivation Clinical Trials

Sleep Promotion in Critically Ill and Injured Patients Cared for in the Intensive Care Unit

Start date: April 2010
Phase: N/A
Study type: Interventional

Sleep deprivation in healthy volunteers is associated with immune dysfunction. This adverse effect of sleep deprivation likely occurs in patients suffering from acute injury and critical illness requiring intensive care unit (ICU) admission. Studies have demonstrated that sleep in ICU patients is highly abnormal. The global hypothesis for this proposal is that a strategy to promote sleep in ICU patients will increase time in rapid eye movement (REM) and slow wave sleep (SWS). This three phase proposal examines the feasibility of a sleep promotion strategy for injured and critically ill patients in the ICU. Phase I (Development and Training): Develop an intervention manual for sleep promotion, Sleep Enhancement Program (SEP), and train ICU staff. Phase II (Validation and Safety): Implement SEP and test for protocol fidelity and safety. Phase III (Efficacy): Conduct a pilot trail to determine efficacy of SEP to improve SWS in ICU patients.

NCT ID: NCT01095198 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia

Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)

Start date: April 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Up to 30% of Canadian women do not participate in Pap smear screening for cervical cancer prevention despite many being members of family practices and having access to family physicians. One reason is reluctance to undergo pelvic examination. The investigators purpose is to determine whether the offer of vaginal self sample collection for oncogenic human papillomavirus (HPV) testing increases participation in cervical cancer screening compared to repeat reminder for Pap smear testing among female family practice members who have not previously responded to invitations for Pap testing.

NCT ID: NCT01099072 Enrolling by invitation - Clinical trials for Attention Deficit Hyperactivity Disorder

Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder

Start date: April 2010
Phase: Phase 2
Study type: Interventional

Attention-deficit hyperactivity disorder (ADHD) is the most common neurobehavioural disorder of childhood. The investigators hypothesized that carnitine would be beneficial for treatment of ADHD, and this could be evaluated in a double blind, randomized, parallel group comparison of carnitine+methylphenidate and methylphenidate +placebo. This will be a six-week, parallel group, randomized clinical trial undertaken in an outpatient child and adolescent clinic at Roozbeh Psychiatric Hospital in Tehran, Iran during April 2010-May 2010. 40 male and female subjects, ages 6 to 17 years with a Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of ADHD will be study population of this trial. At screening, investigators conduct a psychiatric evaluation with the DSM-IV-TR criteria for ADHD and the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime diagnostic interview and perform a complete medical history and physical examination. The diagnosis of ADHD will be confirmed by a child and adolescent psychiatrist before participants will be initiated into the study. All patients will be newly diagnosed. Parents were carefully interview and ask to rate the severity of the DSM-IV-TR ADHD symptoms that their children display at home. Children will be excluded if they have a history or current diagnosis of pervasive developmental disorders, schizophrenia or other psychiatric disorders(DSM-IV axis I); any current psychiatric comorbidity that required pharmacotherapy; any evidence of suicide risk and mental retardation (I.Q. <70). In addition, patients will be excluded if they have a clinically significant chronic medical condition, including organic brain disorder, seizures and, current abuse or dependence on drugs within 6 months. Additional exclusion criteria will be hypertension, hypotension. To participate, parents and children have to be willing to comply with all requirements of the study. After a description of the procedures and purpose of the study, written informed consent will be obtained from each patient's parent or guardian. Informed consent will receive before the administration of any study procedure or dispensing of study medication in accordance with the ethical standards of the investigative site's institutional review board and with the Helsinki declaration of 1975, as revised in 2000. The protocol will be approved by the Institutional Review Board (IRB) of Tehran University of Medical Sciences. Patients will be randomized to receive a carnitine+methylphenidate and methylphenidate +placebo in a 1: 1 ratio using a computer-generated code. All study subjects will be randomly assigned to receive treatment using methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight ) or methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo for a 6 week double blind, randomized clinical. The principal measure of outcome will be the Parent and Teacher ADHD Rating Scale-IV that has been used extensively in Iran in school-age children and provides valid measures of behavioral abnormality and attention trial. Side effects will be systematically recorded throughout the study and will be assessed using a checklist that comprises 20 side effects including psychic, neurologic, autonomic and other side effects, administered by a child psychiatrist on days 7, 21and 42. Side effects, administered by a child psychiatrist on days 7, 21and 42.

NCT ID: NCT01152775 Enrolling by invitation - Clinical trials for The Role of Multimedia on Retention and Comprehension of Key Concepts for Surgical Options in Newly Diagnosed Breast Cancer Patients.

Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding

Start date: April 2010
Phase: N/A
Study type: Interventional

This study will investigate the potential impact of arts-informed, technology-based patient education material, and specifically, the role of multimedia imagery on patient comprehension, perceived satisfaction, anxiety levels, and informed decision-making.

NCT ID: NCT01932047 Enrolling by invitation - Refractory Cancer Clinical Trials

Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment

Start date: April 2010
Phase: N/A
Study type: Observational [Patient Registry]

■ Unmet medical needs for Refractory cancer Conquest - Many advanced cancers are still detected Despite remarkable technological advances for the early diagnosis of cancer in the field last 20 years. In the type of progressive carcinoma is very high malignancy despite a variety of therapeutic target treatment for refractory cancer. The refractory cancer patients who main focus of this research defined as the adult solid tumor patients who have failed standard therapy according to the criteria NCCN / ASCO (American Society of imsangam) / KCSG (Study Group for chemotherapy). The survival rate of refractory cancer patients are estimated to be 30-40% of the total patients with metastatic solid tumors and these refractory cancers are difficult to deal with or control to conventional treatment so shows almost close to 100% mortality. Therefore the new development of therapies for conquer of refractory cancer are urgently required. ■ Preclinical translational research Unmet Needs of Bio-new drug development for conquer of refractory cancer - The stage of preclinical translational research (Translational Research) connects between the early stages of development and clinical trials in the stage drug development. The establishment of foundation based on the translational research is very necessary and this must have proven ability to treat refractory cancer. The most anti-cancer drugs developed by existing preclinical testing method actually does not show a remarkable effect in many cases in the clinical trials, even if showed a remarkable inhibitory cancer effect in animal testing. The exact molecular diagnosis to treat targets and paradigm for the development of new drugs at the same time requires for target treatment. The tailored cell lines by patients and the proven technology by animal models and unmet need for preclinical translational research is increasing

NCT ID: NCT01298947 Enrolling by invitation - Restenosis Clinical Trials

Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions

PHOTOPAC
Start date: April 2011
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of preparing a vessel with photoablation with Spectranetics CVX-300® Excimer laser and laser catheters prior to local Paclitaxel delivery compared to local Paclitaxel delivery without initial photoablation

NCT ID: NCT01333345 Enrolling by invitation - Cataract Clinical Trials

Post-Implant Performance of the EC-3 IOL

Start date: April 2011
Phase: N/A
Study type: Observational

The purpose of this study is to obtain data on the performance of the EC-3 lens at an interval of two years (and beyond) from subjects who were implanted. The primary aim of the study will be to evaluate the presence, if any, of PCO, lens glistening, and other anomalies in the subjects.

NCT ID: NCT01333683 Enrolling by invitation - Hearing Loss Clinical Trials

Tinnitus and Arterial Hypertension

Start date: April 2011
Phase: N/A
Study type: Observational

Many authors link tinnitus to arterial hypertension. The aim of this study is to establish a possible relationship between them, analyze the severity of tinnitus related to arterial hypertension and analyze a possible influence of ototoxic drugs used to treat arterial hypertension